Thrombosis in Pediatric Cardiac Patients

Seminars in Thrombosis and Hemostasis

Volumn 29, Issue 6, 2003, Pages 547-555

  Monagle, Paul ^a,b  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Children; Congenital heart disease; Myocardial infarction; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; APOLIPOPROTEIN B100; HEPARIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMMUNOGLOBULIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN RECEPTOR; STREPTOKINASE; THALLIUM; TISSUE PLASMINOGEN ACTIVATOR; WARFARIN;

ANGIOGRAPHY; ANGIOPLASTY; APHERESIS; BALLOON DILATATION; BLALOCK TAUSSIG ANASTOMOSIS; BLOOD CLOT LYSIS; CLINICAL TRIAL; CONGENITAL HEART DISEASE; CORONARY ARTERY ANEURYSM; CORONARY ARTERY DISEASE; EMBOLECTOMY; FAMILIAL HYPERLIPEMIA; FONTAN PROCEDURE; GENE THERAPY; HEART CATHETERIZATION; HEART INFARCTION; HEART VALVE PROSTHESIS; HUMAN; INCIDENCE; MUCOCUTANEOUS LYMPH NODE SYNDROME; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; STENT; THROMBOEMBOLISM; THROMBOSIS;

ANTICOAGULANTS; CHILD; CORONARY THROMBOSIS; HEART CATHETERIZATION; HEART DISEASES; HEART VALVE PROSTHESIS IMPLANTATION; HUMANS; HYPERLIPIDEMIAS; IATROGENIC DISEASE; INCIDENCE; MUCOCUTANEOUS LYMPH NODE SYNDROME; MYOCARDIAL INFARCTION;

EID: 0347361457     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-815637     Document Type: Review

References (94)

1. Haber C, Kwiterovich PO Jr. Dyslipoproteinemia and xanthomatosis. Pediatr Dermatol 1984;1;261-280
2. West RJ, Lloyd JK. Hypercholesterolemia in childhood. Adv Pediatr 1979;26:1-34
3. Fallat RW, Tsang RC, Glueck CJ. Hypercholesterolemia and hypertriglyceridemia in children. Prev Med 1974;3:390-405
4. Haitas B, Baker SG, Meyer TE, et al. Natural history and cardiac manifestations of homozygous familial hypercholesterolaemia. QJ Med 1990;76:731-740
5. Rose V, Wilson G, Steiner G. Familial hypercholesterolemia: report of coronary death at age 3 in a homozygous child and prenatal diagnosis in a heterozygous sibling. J Pediatr 1982; 100:757-759
6. Sprecher DL, Schaefer EJ, Kent KM, et al. Cardiovascular features of homozygous familial hypercholesterolemia: analysis of 16 patients. Am J Cardiol 1984;54:20-30
7. Hoeg JM. Familial hypercholesterolemia. What the zebra can teach us about the horse. JAMA 1994;271:543-546
8. Goldstein JL, Brown MS. The LDL receptor defect in familial hypercholesterolemia. Implications for pathogenesis and therapy. Med Clin North Am 1982;66:335-362
9. Williams ML. Death of a child as a result of familial hypercholesterolaemia Med J Aust 1989;150:93-94
10. Clemens P, Beisiegel U, Steinhagen-Thiessen E. Family study in familial hypercholesterolemia with a receptor-negative homozygous 9-year-old boy. Helv Paediatr Acta 1986;41:173-182
11. Goldstein J, Brown M. Familial hyercholesterolemia. In: Stanbury JB, ed. Metabolic Basis of Inherited Disease, Chapter 33. New York: McGraw Hill; 1989:672-712
12. Leonard JV, Clarke M, Macartney FJ, et al. Progression of atheroma in homozygous familial hypercholesterolaemia during regular plasma exchange (letter). Lancet 1981;2:811
13. Raper SE, Grossman M, Rader DJ, et al. Safety and feasibility of liver-directed ex vivo gene therapy for homozygous familial hypercholesterolemia Ann Surg 1996;223: 116-126
14. Celermajer DS, Sorensen KE, Gooch VM, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992;340:1111-1115
15. Sorensen KE, Celermajer DS, Georgakopoulos D, et al. Impairment of endothelium-dependent dilation is an early event in children with familial hypercholesterolemia and is related to the lipoprotein(a) level. J Clin Invest 1994;93:50-55
16. Hegele RA, Connelly PW, Cullen-Dean G, et al. Elevated plasma lipoprotein(a) associated with abnormal stress thallium scans in children with familial hypercholesterolemia. Am J Cardiol 1993;72:402-406
17. Mouratidis B, Vaughan-Neil EF, Gilday DL, et al. Detection of silent coronary artery disease in adolescents and young adults with familial hypercholesterolemia by single-photon emission computed tomography thallium-201 scanning. Am J Cardiol 1992;70:1109-1112
18. Rubinsztein DC, Raal FJ, Seftel HC, et al. Characterization of six patients who are double heterozygotes for familial hypercholesterolemia and familial defective apo B-100. Arterioscler Thromb 1993;13:1076-1081
19. Rauh G, Keller C, Kormann B, et al. Familial defective apolipoprotein B100: clinical characteristics of 54 cases. Atherosclerosis 1992;92:233-241
20. Salen G, Horak I, Rothkopf M, et al. Lethal atherosclerosis associated with abnormal plasma and tissue sterol composition in sitosterolemia with xanthomatosis. J Lipid Res 1985; 26:1126-1133
21. Kawasaki T. Discovery of Kawasaki disease (muco-cutaneous lymph node syndrome) and its research activities. Nippon Rinsho 1976;34:222-227
22. Durongpisitkul K, Gururaj VJ, Park JM, et al. The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment. Pediatrics 1995;96:1057-1061
23. Furusho K, Kamiya T, Nakano H, et al. High-dose intravenous gammaglobulin for Kawasaki disease. Lancet 1984;2: 1055-1058
24. Newburger JW, Takahashi M, Burns JC, et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 1986;315:341-347
25. Newburger JW, Takahashi M, Beiser AS, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 1991;324:1633-1639
26. Koren G, Rose V, Lavi S, et al. Probable efficacy of high-dose salicylates in reducing coronary involvement in Kawasaki disease. JAMA 1985;254:767-769
27. Daniels SR, Specker B, Capannari TE, et al. Correlates of coronary artery aneurysm formation in patients with Kawasaki disease. Am J Dis Child 1987;141:205-207
28. Williams RV, Wilke VM,Tani LY, et al. Does abciximab enhance regression of coronary aneurysms resulting from Kawasaki disease? Pediatrics 2002;109:E4
29. Suzuki A, Kamiya T, Ono Y, et al. Myocardial ischemia in Kawasaki disease: follow-up study by cardiac catheterization and coronary angiography. Pediatr Cardiol 1988;9:1-5
30. Kato H, Sugimura T, Akagi T, et al. Long-term consequences of Kawasaki disease. A 10-to 21-year follow-up study of 594 patients. Circulation 1996;94:1379-1385
31. Gersony WM. Diagnosis and management of Kawasaki disease. JAMA 1991;265:2699-2703
32. Tatara K, Kusakawa S. Long-term prognosis of giant coronary aneurysm in Kawasaki disease: an angiographic study. J Pediatr 1987;111:705-710
33. The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993;329:1615-1622
34. Kitamura S, Kameda Y, Kawashima Y Surgery for Kawasaki disease. Adv Card Surg 1997;9:177-194
35. Smith C, Green RM. Pediatric vascular injuries. Surgery 1981;90:20-31
36. Perry MO. Iatrogenic injuries of arteries in infants. Surg Gynecol Obstet 1983;157:415-418
37. Burrows PE, Benson LN, Williams WG, et al. Iliofemoral arterial complications of balloon angioplasty for systemic obstructions in infants and children Circulation 1990;82:1697-1704
38. Mortensson W, Hallbook T, Lundstrom NR. Percutaneous catheterization of the femoral vessels in children. II. Thrombotic occlusion of the catheterized artery: frequency and causes. Pediatr Radiol 1975;4:1-9
39. Mortensson W. Angiography of the femoral artery following percutaneous catheterization in infants and children. Acta Radiol 1976;17:581-593
40. Padmanabhan J, Krovetz LJ, Varghese PJ, et al. Effect of topical papaverine in preventing thrombosis following arteriotomies. A double-blind study in infants and children. J Pediatr 1972;81:792-793
41. Freed MD, Keane JF, Rosenthal A. The use of heparinization to prevent arterial thrombosis after percutaneous cardiac catheterization in children. Circulation 1974;50:565-569
42. Ino T, Benson LN, Freedom RM, et al. Thrombolytic therapy for femoral artery thrombosis after pediatric cardiac catheterization. Am Heart J 1988;115:633-639
43. Rao PS, Thapar MK, Rogers JH Jr, et al. Effect of intraarterial injection of heparin on the complications of percutaneous arterial catheterization in infants and children. Cathet Cardiovasc Diagn 1981;7:235-246
44. Butt W, Shann F, McDonnell G, et al. Effect of heparin concentration and infusion rate on the patency of arterial catheters. Crit Care Med 1987;15:230-232
45. Saxena A, Gupta R, Kumar RK, et al. Predictors of arterial thrombosis after diagnostic cardiac catheterization in infants and children randomized to two heparin dosages. Cathet Cardiovasc Diagn 1997;41:400-403
46. McFadden PM, Ochsner JL, Mills N. Management of thrombotic complications of invasive arterial monitoring of the upper extremity. J Cardiovasc Surg (Torino) 1983;24: 35-39
47. Vlad P, Hohn A, Lambert EC. Retrograde arterial catheterization of the left heart. Experience with 500 infants and children. Circulation 1964;29:787-793
48. Jones J, Hunter D. Consensus methods for medical and health services research. BMJ 1995;311:376-380
49. Stanger P, Heymann MA, Tarnoff H, et al. Complications of cardiac catheterization of neonates, infants, and children. A three-year study. Circulation 1974;50:595-608
50. Hurwitz RA, Franken EA Jr, Girod DA, et al. Angiographic determination of arterial patency after percutaneous catheterization in infants and small children. Circulation 1977;56: 102-105
51. Girod DA, Hurwitz RA, Caldwell RL. Heparinization for prevention of thrombosis following pediatric percutaneous arterial catheterization. Pediatr Cardiol 1982;3:175-180
52. Wessel DL, Keane JF, Fellows KE, et al. Fibrinolytic therapy for femoral arterial thrombosis after cardiac catheterization in infants and children. Am J Cardiol 1986;58:347-351
53. Gagnon RM, Goudreau E, Joyal F, et al. The role of intravenous streptokinase in acute arterial occlusions after cardiac catheterization. Cathet Cardiovasc Diagn 1985;11:409-412
54. Zenz W, Muntean W, Beitzke A, et al. Tissue plasminogen activator (alteplase) treatment for femoral artery thrombosis after cardiac catheterisation in infants and children. Br Heart J 1993;70:382-385
55. Brus F, Witsenburg M, Hofhuis WJ, et al. Streptokinase treatment for femoral artery thrombosis after arterial cardiac catheterisation in infants and children. Br Heart J 1990;63: 291-294
56. Kothari SS, Kumar RK, Varma S, et al. Thrombolytic therapy in infants for femoral artery thrombosis following cardiac catheterisation. Indian Heart J 1996;48:246-248
57. Freed MD, Rosenthal A, Fyler D. Attempts to reduce arterial thrombosis after cardiac catheterization in children: use of percutaneous technique and aspirin. Am Heart J 1974;87:283-286
58. Kern IB. Management of children with chronic femoral artery obstruction. J Pediatr Surg 1977;12:83-90
59. Taylor LM Jr, Troutman R, Feliciano P, et al. Late complications after femoral artery catheterization in children less than five years of age. J Vasc Surg 1990;11:297-304
60. Celermajer DS, Robinson JT, Taylor JF. Vascular access in previously catheterised children and adolescents: a prospective study of 131 consecutive cases. Br Heart J 1993;70:554-557
61. Taussig HB. Long-time observations on the Blalock-Taussig operation IX. Single ventricle (with apex to the left). Johns Hopkins Med J 1976;139:69-76
62. Truccone NJ, Bowman FO Jr, Malm JR, et al. Systemic-pulmonary arterial shunts in the first year of life. Circulation 1974;49:508-511
63. Godart F, Qureshi SA, Simha A, et al. Effects of modified and classic Blalock-Taussig shunts on the pulmonary arterial tree. Ann Thorac Surg 1998;66:512-517
64. Tsai KT, Chang CH, Lin PJ. Modified Blalock-Taussig shunt: statistical analysis of potential factors influencing shunt outcome. J Cardiovasc Surg (Torino) 1996;37:149-152
65. Gladman G, McCrindle BW, Williams WG, et al. The modified Blalock-Taussig shunt: clinical impact and morbidity in Fallot's tetralogy in the current era. J Thorac Cardiovasc Surg 1997;114:25-30
66. Bogats G, Kertesz E, Katona M, et al. Modified Blalock-Taussig shunt using allograft saphenous vein: six years' experience. Ann Thorac Surg 1996;61:58-62
67. Ohuchi H, Okabe H, Nagata N, et al. Long-term patency after the Blalock-Taussig operation - comparison between classic and modified shunts. Nippon Kyobu Geka Gakkai Zasshi 1996;44:1108-1113
68. Zahn EM, Chang AC, Aldousany A, et al. Emergent stent placement for acute Blalock-Taussig shunt obstruction after stage 1 Norwood surgery. Cathet Cardiovasc Diagn 1997; 42:191-194
69. Takanashi Y, Tomizawa Y, Noishiki Y, et al. Calcified EPTFE vascular prosthesis in the Blalock-Taussig shunt after 4 years of implantation: a case report. Kyobu Geka 1997;50: 71-73
70. Berger RM, Bol-Raap G, Hop WJ, et al. Heparin as a risk factor for perigraft seroma complicating the modified Blalock-Taussig shunt. J Thorac Cardiovasc Surg 1998;116:286-292
71. Klinge J, Hofbeck M, Ries M, et al. Thrombolysis of modified Blalock-Taussig shunts in childhood with recombinant tissue-type plasminogen activator. Z Kardiol 1995;84:476-480
72. Alcibar J, Cabrera A, Onate A, et al. Angioplasty of the stenotic Blalock-Taussig. Rev Esp Cardiol 1994;47:819-823
73. Ries M, Singer H, Hofbeck M. Thrombolysis of a modified Blalock-Taussig shunt with recombinant tissue plasminogen activator in a newborn infant with pulmonary atresia and ventricular septal defect. Br Heart J 1994;72:201-202
74. Boulden TF, Tonkin IL, Burton EM, et al. Case of the day. Pediatric. Mycotic pseudoaneurysm and thrombosis of modified left Blalock-Taussig shunt. Radiographics 1990;10:119-121
75. Ahmadi A, Mocellin R, Henglein D, et al. Modified Blalock-Taussig anostomosis. Its significance within the scope of surgical treatment of Tetralogy of Fallot. Monatsschr Kinderheilkd 1988;136:130-134
76. Brandt B, Camacho JA, Mahoney LT, et al. Growth of the pulmonary arteries following Blalock-Taussig shunt. Ann Thorac Surg 1986;42:S1-S4
77. Tamisier D, Vouhe PR, Vernant F, et al. Modified Blalock-Taussig shunts: results in infants less than 3 months of age. Ann Thorac Surg 1990;49:797-801
78. Mullen JC, Lemermeyer G, Bentley MJ. Modified Blalock-Taussig shunts: to heparinize or not to heparinize? Can J Cardiol 1996;12:645-647
79. Rajani RM, Dalvi BV, Kulkarni HL, et al. Acutely blocked Blalock-Taussig shunt following cardiac catheterization: successful recanalization with intravenous streptokinase. Am HeartJ 1990;120:1238-1239
80. Hijazi ZM. Stenting for postoperative congenital heart disease in infants. Cathet Cardiovasc Diagn 1997;42:195-198
81. Monagle P, Cochrane A, McCrindle B, et al. Thromboembolic complications after Fontan procedures - the role of prophylactic anticoagulation. J Thorac Cardiovasc Surg 1998;115:493-498
82. Zahn EM, Lima VC, Benson LN, et al. Use of endovascular stents to increase pulmonary blood flow in pulmonary atresia with ventricular septal defect. Am J Cardiol 1992;70:411-412
83. Sade R, Ballenger JF, Hohn A, et al. Cardiac valve replacement in children: Comparison of tissue with mechanical prostheses. J Thorac Cardiovasc Surg 1979;78:123-127
84. Brown JW, Dunn JM, Spooner E, et al. Late spontaneous disruption of a porcine xenograft mitral valve. Clinical, hemodynamic, echocardiographic, and pathological findings. J Thorac Cardiovasc Surg 1978;75:606-611
85. Geha AS, Laks H, Stansel HC Jr, et al. Late failure of porcine valve heterografts in children. J Thorac Cardiovasc Surg 1979; 78:351-364
86. Silver MM, Pollock J, Silver MD, et al. Calcification in porcine xenograft valves in children. Am J Cardiol 1980;45: 685-689
87. Dunn JM. Porcine valve durability in children. Ann Thorac Surg 1981;32:357-368
88. Williams WG, Pollack JC, Geiss DM, et al. Experience with aortic and mitral valve replacement in children. J Thorac Cardiovasc Surg 1981;81:326-333
89. Miller D, Stinson E, Oyer P, et al. The durability of porcine xenograft valves and conduits in children. Circulation 1982; 66(suppl I, Pt 2):I172-I185
90. Odell J. Calcification of porcine bioprostheses in children. In: Cohn L, Gallucci V, eds. Cardiac Bioprostheses: Proceedings of the Second International Symposium. New York: Yorke Medical Books; 1982:231
91. Williams DB, Danielson GK, McGoon DC, et al. Porcine heterograft valve replacement in children. J Thorac Cardiovasc Surg 1982;84:446-450
92. Champsaur G, Robin J, Tronc F, et al. Mechanical valve in aortic position is a valid option in children and adolescents. Eur J Cardiothorac Surg 1997;11:117-122
93. Yankah AC, Alexi-Meskhishvili V, Weng Y, et al. Performance of aortic and pulmonary homografts in the right ventricular outflow tract in children. J Heart Valve Dis 1995;4: 392-395
94. Monagle P, Michelson AD, Bovill E, et al. Antithrombotic therapy in children. Chest 2001;119:344S-370S